In addition, Himuro et al. showed that NSCLC patients treated with pembrolizumab or nivolumab who had high levels of sPD-1 after 6 weeks of treatment exhibited a longer OS (median: 821 vs 183 days) than patients with levels below this threshold [78]. The gene discussed is HOXD13; the disease is non-small cell lung carcinoma.